dr zafar semaglutide M. Zafar, MD, SC Romius Beta v2

No significant pharmacokinetic interactions have been reported between semaglutide and these agents

Most GLP-1 drugs don't have dedicated J-codes

Still, patients need clear guidance

A blood glucose stabilizing diet, aerobic and resistance exercise, sleep optimization, and stress reduction all potentiate these peptide effects

In the safety outcomes trial (DEVOTE), a total of 1429 (37.4%) of the 3818 TRESIBA-treated patients with type 2 diabetes had an eGFR less than 60 mL/min/1.73 m2, and 108 (2.8%) subjects had an eGFR less than 30 mL/min/1.73 m2

IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors